Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 USD | +1.37% | +2.78% | +23.33% |
May. 15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
May. 15 | Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024 | CI |
Evolution of the average Target Price on Immutep ADR
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Immutep ADR
Canaccord Genuity | |
Baird | |
Maxim | |
Ladenburg Thalmann |
EPS Revisions
- Stock Market
- Equities
- IMM Stock
- IMMP Stock
- Consensus Immutep ADR